HY-1 induces G(2)/M cell cycle arrest in human colon cancer cells through the ATR-Chk1-Cdc25C and Weel pathways

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Cancer Research

Background:

• Podophyllotoxin analogues are explored for anticancer properties.
• DNA topoisomerase II is a validated target for cancer chemotherapy.
• Developing novel inhibitors with multitargeting capabilities is crucial.

Purpose of the Study:

• Synthesize and evaluate the novel aroylthiourea analogue of podophyllotoxin, HY-1.
• Investigate HY-1's antiproliferative activity and mechanism of action in cancer cell lines.
• Determine HY-1's inhibitory effect on DNA topoisomerase II activity.

Main Methods:

• Synthesis of HY-1 (4β-[benzoyl-thioureido]-4-deoxypodophyllotoxin).
• Assessment of antiproliferative effects across seven human cancer cell lines.
• Analysis of cell cycle progression (G2/M phase arrest) in HCT116 cells.
• Evaluation of DNA topoisomerase II inhibition using kinetoplast DNA decatenation assays.
• Investigation of cell cycle regulatory pathways (ATR-Chk1-Cdc25C, Weel).

Main Results:

• HY-1 demonstrated significant antiproliferative effects on multiple cancer cell lines.
• The compound induced G2/M phase cell cycle arrest in HCT116 cells.
• HY-1 potently inhibited DNA topoisomerase II-mediated decatenation in a dose-dependent manner.
• Mechanistic studies revealed HY-1's role in cdc2 phosphorylation and kinase activity reduction via ATR-Chk1-Cdc25C and Weel pathways.

Conclusions:

• The novel podophyllotoxin analogue HY-1 is a potent inhibitor of DNA topoisomerase II.
• HY-1 exhibits significant anticancer activity through cell cycle arrest at the G2/M phase.
• The findings support the development of HY-1 as a potential therapeutic agent for human colon cancer and other malignancies.